胰高血糖素样肽-1受体激动剂治疗与银屑病关节炎相关及代谢结局改善相关:两项队列的回顾性分析
治疗后体重显著下降-6.43 kg(95%CI -9.5至-2.0;P<0.0001),60%患者体重下降≥5%。CRP、疼痛评分和甘油三酯显著降低,且体重每下降1%与PsA疾病活动度评分、压痛关节数等改善相关。
要点
- GLP-1RA治疗与PsA患者显著体重下降及炎症、疼痛和代谢指标改善相关
- 体重下降程度与银屑病关节炎结局改善呈比例关系
- 需前瞻性对照研究评估GLP-1RA在PsA管理中的作用
核心结论
- 在真实世界研究中,GLP-1RA治疗与PsA患者具有临床意义的体重下降及全身炎症、疼痛和心血管代谢标志物改善相关。
- 银屑病结局的改善与体重下降程度成比例。
研究设计与样本
- 收集GLP-1RA起始前后一年内临床就诊的PsA疾病活动度数据和心血管代谢参数,以及人口学和合并症信息。
主要发现
- 治疗后体重显著下降-6.43 kg(95%CI -9.5至-2.0;P<0.0001),60%患者体重下降≥5%。
- C反应蛋白水平下降-1.1 mg/L(P=0.002),疼痛评分下降-1.0(P=0.01),甘油三酯水平下降-0.35 mmol/L(P=0.02)。
- 体重每下降1%与银屑病关节炎疾病活动度评分改善相关(β=-0.49,95%CI -0.94至-0.03)。
- 体重每下降1%与压痛关节数改善相关(β=-0.18,95%CI -0.32至-0.05)。
- 体重每下降1%与EuroQol五维度评分改善相关(β=0.0016,95%CI 0.008至0.023)。
临床怎么用
- 对于合并肥胖的PsA患者,GLP-1RA治疗可能作为改善体重、炎症和代谢指标的综合管理策略之一。
- 临床中可关注PsA患者体重下降程度,其与关节症状和代谢指标改善呈比例关系。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Obesity is highly prevalent in psoriatic arthritis (PsA) and is associated with worse disease outcomes. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are increasingly being used for weight loss and diabetes, but their impact on PsA outcomes remains unclear. We aimed to characterize patients with PsA initiating GLP-1RAs and assess longitudinal changes in weight, PsA activity, and cardiometabolic parameters. METHODS: We conducted a retrospective analysis of patients with PsA who initiated GLP-1RAs. PsA disease activity data and cardiometabolic parameters from clinical visits within one year before and after GLP-1RA initiation, along with demographics and comorbidities, were collected. RESULTS: Forty-eight patients with a median body mass index of 34.9 were included. Significant weight loss was observed posttreatment (-6.43 kg, 95% confidence interval [CI] -9.5 to -2.0; P < 0.0001), with 60% losing ≥5% of their baseline bodyweight. C-reactive protein levels (-1.1 mg/L; P = 0.002), pain scores (-1.0; P = 0.01), and triglyceride levels (-0.35 mmol/L; P = 0.02) decreased significantly. Each 1% reduction in body weight was associated with significant improvements in the Disease Activity in Psoriatic Arthritis score (β = -0.49, 95% CI -0.94 to -0.03), tender joint count (β = -0.18, 95% CI -0.32 to -0.05), EuroQol 5-domain (β = 0.0016, 95% CI 0.008-0.023), low-density lipoprotein cholesterol levels (β = -0.05, 95% CI -0.10 to -0.003), and systolic blood pressure (β = -0.67, 95% CI -1.18 to -0.15). CONCLUSION: In this real-world study, GLP-1RA therapy in PsA was associated with clinically meaningful weight loss and improvements in systemic inflammation, pain, and cardiometabolic markers. Improvements in psoriatic outcomes were proportional to the degree of weight loss. These findings warrant further investigation in prospective controlled studies to evaluate the role of GLP-1RAs in PsA management and comorbidities.
引用
- Haberman RH, Rice AL, Chen K, et al. Glucagon-Like Peptide-1 Receptor Agonist Therapy Is Associated With Improvement in Psoriatic Arthritis-Related and Metabolic Outcomes: A Retrospective Analysis of Two Cohorts. Arthritis Rheumatol. 2026. PMID: 41940492. doi:10.1002/art.70170
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。